ETV1 and prostate carcinoma: Recent experiments from our group have also indicated that YK-4-279 is able to inhibit ERG and ETV1 fusion-positive prostate cancer cell lines [33], and the activity and function of the enantiomers should be further investigated in prostate cancer.